EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Central composite design assisted optimization of RP-HPLC method for simultaneous estimation of linagliptin and empagliflozin using AQbD perspective

Khushbu Patel, Zeel Modi, Chhaganbhai N. Patel

Discover Chemistry · 11.07.2026 · 3 (1)

DOI: 10.1007/s44371-026-00870-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Chemistry, online erschienen am 11.07.2026. Verfasst von Khushbu Patel und 2 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Linagliptin and Empagliflozin are widely used antidiabetic agents, and their combined dosage forms require reliable analytical methods for quality control. Conventional chromatographic method development often lacks robustness; therefore, the application of QbD principles ensures systematic optimization and enhanced method performance. Methodology In the QbD strategy, a central composite design (CCD) was employed to evaluate the influence of critical method parameters, particularly the composition of the mobile phase and the flow rate. The interaction effects of these parameters on critical responses, including retention time and resolution of Linagliptin and Empagliflozin, were analyzed using response surface plots to establish optimal chromatographic conditions. Chromatographic separation was achieved using a C18 column (250 × 4.6 mm, 5 μm) with an isocratic elution system. The mobile phase consisted of Methanol and Acetonitrile (90:10, v/v) delivered at a flow rate of 1 mL/min. Detection was carried out using a photodiode array (PDA) detector at 225 nm.

Results

The method demonstrated good linearity over the concentration range of 2.5–12.5 µg/mL for Linagliptin and 5–25 µg/mL for Empagliflozin, with correlation coefficients (r²) of 0.993 and 0.991, respectively. The optimized method provided satisfactory resolution with 4.174 min of Linagliptin and 2.900 min for Empagliflozin retention times, and validation parameters confirmed that the method is precise, accurate, and reproducible.

Conclusion

The developed RP-HPLC method based on QbD principles is simple, robust, and reliable for the simultaneous estimation of Linagliptin and Empagliflozin in pharmaceutical dosage forms. The application of CCD and response surface methodology ensures systematic optimization and enhances method performance, making it suitable for routine quality control analysis.

Zitieren

APA

Patel, K., Modi, Z., & Patel, C. N. (2026). Central composite design assisted optimization of RP-HPLC method for simultaneous estimation of linagliptin and empagliflozin using AQbD perspective. Discover Chemistry, 3(1). https://doi.org/10.1007/s44371-026-00870-8

Vancouver

Patel K, Modi Z, Patel CN. Central composite design assisted optimization of RP-HPLC method for simultaneous estimation of linagliptin and empagliflozin using AQbD perspective. Discover Chemistry. 2026;3(1). doi:10.1007/s44371-026-00870-8

BibTeX
@article{Patel2026,
  author = {Patel, Khushbu and Modi, Zeel and Patel, Chhaganbhai N.},
  title = {Central composite design assisted optimization of RP-HPLC method for simultaneous estimation of linagliptin and empagliflozin using AQbD perspective},
  journal = {Discover Chemistry},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.1007/s44371-026-00870-8}
}
Kostenlos starten →